Pharmachologic Prophylaxis for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is one of the most burdensome adverse events, occurs in about 3 to 15 percent of patients after the procedure. Various and extensive attempts have been made to find proper prophylaxis for PEP. Nowadays, pharmacologic agents consist one of the pivotal axis for prophylaxis for PEP. In this review article, we tried to overview pharmacologic prophylaxis including non-steroidal anti-inflammatory drugs, aggressive hydration, protease inhibitors, exocrine pancreatic secretion inhibitors, and nitrates from recent updated results of randomized controlled studies and key meta-analyses.

MODIFICATION OF THE PFEFFER PANCREONECROSIS MODEL FOR ASSESSING PANCREATIC SECRETION IN THE ACUTE PERIOD OF DISEASE

A preliminary experimental study: Measurement of exocrine pancreatic secretion was performed on Wistar rats after an induction of acute pancreatitis by ‘closed duodenal loop’ (CDL) method (total number of animals = 39). After 24 hrs duration of AP the CDL content was evacuated by syringe and tested for amylase level (IU/ml). A near normal output remained in most animals (1987,35 ± 558,26, n = 12); moderately decreased output was 264,67 ± 162,74 (n = 9), and cessation of the output in n = 3 (0,6 ± 0,3) (q < 0,01 for each group). So, in our series the exocrine pancreatic output was found diverging largely with a normal secretion prevailing. Further study is warranted for some conclusive results to obtain.